New Two-Drug attack on Tough-to-Treat cancers begins human testing
Disease control
Ongoing
This study is testing a new combination of two drugs, D-1553 and IN10018, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe dose for the combination and to see if it can shrink tumors in patients with can…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC